Get Started

LYCA

NASD Lycia Therapeutics, Inc.
Oct 26, 2026 · 8:05 AM ET LAST TRADE Market Closed

$26.50 ↓ -3.50 (-11.67%) Trading Down from the previous close of $30.00

YTD change
-11.67%
vs 20-day SMA
N/A
vs 200-day SMA
N/A

Price ranges

Previous day
$22.19 $36.49
open $28.55 close $30.00
+$1.45 (+5.08%)
Today
$0.00 $0.00
$26.50
Past week
$0.00 $30.00
from $30.00 now $26.50
-$3.50 (-11.67%)
Past month
$0.00 $30.00
from $30.00 now $26.50
-$3.50 (-11.67%)
This year
$22.19 $36.49
from $30.00 now $26.50
-$3.50 (-11.67%)

Price & Performance

+0.00 (+0.00%) / 6M

No chart data available

Signals & Sentiment

Momentum, market sentiment, and recent alerts

N/A
  • The stock is 27.4% away from all-time highs of $36.49
  • LYCA is down 12% since the beginning of the year
  • LYCA is down 12% over the past 12 months
  • LYCA is down 12% over the past 1 month

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $1.7B

Balance sheet & scale

IncomeN/A
Revenue$6.7M
Cash$79.1M
Debt$205.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $1.4B

Lycia Therapeutics is the operator of a biotechnology firm that aims to research and produce first-in-class therapies. The company's lysosomal targeting chimeras (LYTACs) platform is used to develop therapeutics that degrade extracellular and membrane-bound proteins that drive a variety of difficult-to-treat diseases, such as cancer and autoimmune conditions, allowing doctors to obtain drugs to cure patients.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.